PDK-1/Akt signaling inhibitors

Details PDK-1/Akt signaling inhibitors PDK-1/Akt signaling inhibitors

2010-09-23

2011-12-20

Shameem, Golam M M (Department: 1622)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S250000, C548S373100, C548S375100, C514S403000

Reexamination Certificate

active

08080574

ABSTRACT:
Use of a new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula I for inducing apoptosis in unwanted rapidly proliferating cells, for treating, inhibiting, or delaying the onset of cancer, and for preventing restenosis in a subject that has undergone an angioplasty or stent:wherein X is selected from the group consisting of alkyl and haloalkyl; Ar is an aryl radical selected from the group consisting of phenyl, biphenyl, naphthyl, anthryl, phenanthryl, and fluorenyl; and wherein Ar is optionally substituted with one or more radicals selected from the group consisting of halo, C1-C4alkyl, C1-C4haloalkyl, azido, C1-C4azidoalkyl, aryl, akylaryl, haloaryl, haloalkylaryl, and combinations thereof; and R is selected from the group consisting of nitrile, acetonitrile, ethylnitrile, propylnitrile, carboxamide, amidine, tetrazole, oxime, hydrazone, acetamidine, aminoacetamide, guanidine, and urea.

REFERENCES:
patent: 5091387 (1992-02-01), Evans et al.
patent: 5134142 (1992-07-01), Matsuo
patent: 5206240 (1993-04-01), Baldwin et al.
patent: 5466823 (1995-11-01), Talley
patent: 5521207 (1996-05-01), Graneto
patent: 5550147 (1996-08-01), Matsuo
patent: 5639777 (1997-06-01), Lee
patent: 5670509 (1997-09-01), Evans et al.
patent: 5760068 (1998-06-01), Talley
patent: 5972986 (1999-10-01), Seibert
patent: 6025353 (2000-02-01), Masferrer
patent: 6172239 (2001-01-01), Labeeuw et al.
patent: 6673818 (2004-01-01), Brown et al.
patent: 7026346 (2006-04-01), Chen et al.
patent: 7183306 (2007-02-01), Shirai
patent: 7576116 (2009-08-01), Chen
patent: 2002/0032238 (2002-03-01), Priepke
patent: 2006/0079566 (2006-04-01), Chen
patent: 2006/0142368 (2006-06-01), Chen et al.
patent: 2008/0269309 (2008-10-01), Chen
patent: 2009/0111799 (2009-04-01), Chen et al.
patent: 418845 (1991-03-01), None
patent: 431943 (1991-06-01), None
patent: 444945 (1991-09-01), None
patent: 554829 (1993-08-01), None
patent: 1512396 (2005-03-01), None
patent: 120841 (2007-07-01), None
patent: 95/15315 (1995-06-01), None
patent: 96/41626 (1996-12-01), None
patent: 03/086287 (2003-10-01), None
patent: 2005/044130 (2005-05-01), None
Notice of Allowance from U.S. Appl. No. 10/409,502 dated Oct. 25, 2005.
Response from U.S. Appl. No. 10/409,502 dated Aug. 17, 2005.
Office action from U.S. Appl. No. 10/409,502 dated Feb. 17, 2005.
Response from U.S. Appl. No. 10/409,502 dated Dec. 16, 2004.
Office action from U.S. Appl. No. 10/409,502 dated Jul. 16, 2004.
Office action from U.S. Appl. No. 10/957,925 dated Mar. 30, 2007.
Response from U.S. Appl. No. 10/957,925 dated Jan. 4, 2007.
Office action from U.S. Appl. No. 10/957,925 dated Oct. 4, 2006.
Response from U.S. Appl. No. 10/957,925 dated Aug. 18, 2006.
Office action from U.S. Appl. No. 10/957,925 dated Apr. 18, 2006.
Office action from U.S. Appl. No. 11/354,528 dated Jan. 31, 2008.
Notice of Allowance from U.S. Appl. No. 11/864,612 dated Apr. 10, 2009.
Written Opinion from International Application No. PCT/US04/32732 dated Jul. 25, 2005.
International Search Report from International Application No. PCT/US04/32723 dated Mar. 9, 2005.
International Search Report from International Application No. PCT/US03/10738 dated Jan. 21, 2004.
Written Opinion from International Application No. PCT/US03/10738 dated Jun. 4, 2004.
Supplemental Search Report from European Application No. 03723936 dated Dec. 2, 2005.
Supplemental Search Report from European Application No. 04816902 dated Jul. 26, 2007.
Examination Report from European Application No. 03723936 dated Oct. 30, 2007.
Office action from Chinese Application No. 0661255 dated Dec. 7, 2007.
Gastrointestinal (GI) Effects-risk of GI Ulceration, bleeding and perforation, printed on Mar. 19, 2002 from http://www.celebrex.com/us—prescribing—info.asp (9 pgs.).
HCAPLUS 1994:8589, CAS Registry No. 151506-47-7.
Product catalog, Cayman Chemical Company, item 10008005 (OSU03012), May 2006, 3 pgs.
“Special Project Angiogenesis. Angiogenesis and Cancer,” printed on Dec. 4, 2001 from http://www.med.unibs.it:8080/˜airc/cancer.html, 3 pgs.
“Special Project Angiogenesis. Angiogenesis: a Brief Introduction,” printed on Dec. 4, 2001 from http://www.med.unibs.it:8080/˜airc/angiogen.html, 4 pgs.
“Understanding Angiogenesis,” printed on Dec. 4, 2001 from http://www.angio.org/understanding/content—understanding.html, 6 pgs.
Workshop #2405. Impact of Apoptosis (Programmed Cell Death) for Clinical Laboratory Sciences, printed on Oct. 22, 2001 from http://www.3dresearch.com/˜apoptosis/cancer/, 6 pgs.
Devleeschauwer et al., “Remarkably Mild and Simple Preparations of Sulfinates, Sulfonyl Chlorides and Sulfonamides from Thioanisoles”, Synlett, Thieme International, Stuttgart, DE, No. 4, 375-377 (Apr. 1997).
Grosch et al., “COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib,” FASEB J 15 (14): 2742-4 (2001).
Hsu et al., “The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2,” J Biol Chem, 275: 11397-403 (2000).
Johnson et al., “The cyclooxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: A Plausible Link with its antitumor effect and cardiovascular risks,” Biochem J 363, 831-837 (2002).
Johnson et al., “Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells”, Adv Enzyme Regul 41: 221-35 (2001).
Penning et al., “Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-5[4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-y1]benzenesulfonamide (SC-58635, celecoxib),” J Med Chem, 40: 1347-65 (1997).
Song et al., “Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitors-induced apoptosis in prostate cancer cells,” J Natl Cancer Inst 94: 585-591 (2002).
Zhu et al., “Using Cycoloxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents”, J Natl Cancer Insti 94: 1745-1757 (2002).
Zhu et al., “From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors,” Cancer Research 64: 4309-4318 (Jun. 15, 2004).
Arico et al.; Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line; The Journal of Biological Chemistry, vol. 277, No. 31, Issue of Aug. 2, 2002, pp. 27613-27621.
Buchdunger et al.; Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylaminopyrimidine Derivative; Cancer Research 56, 100-104, Jan. 1, 1996.
Fabbro et al.; Protein kinases as targets for anticancer agents: from inhibitors to useful drugs; Elsevier Science Inc., Pharmacology & Therapeutics 93 (2002) 79-98.
Groesch et al. (2001): STN International CAPLUS database, Columbus (Ohio), Accession No. 2001: 912333.
Harris et al.: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000 ; 60: 2101-3.
Steinbach et al.; The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis; The New England Journal of Medicine, vol. 242, No. 26, pp. 1946-1952 (2000).
Vivanco et al.; The Phosphatidlinositol 3-Kinase-AKT Pathway in Human Cancer; Nature Reviews | Cancer, vol. 2, Jul. 2002, pp. 489-501.
Office action from U.S. Appl. No. 12/179,134 dated Dec. 14, 2010.
Office action from U.S. Appl. No. 12/476,772 dated Sep. 7, 2010.
Amendment from U.S. Appl. No. 12/476,772 dated Dec. 7, 2010.
Amendment from U.S. Appl. No. 12/476,772 dated Dec. 20, 2010.
Office action from Canadian Application No. 2,566,846 dated Dec. 2, 2010.
Office action from Chinese Application No. 200480036007.3 dated Dec. 7, 2007.
Amendment from Chinese Application No. 200480036007.3 dated May 30, 2008.
Notice of Allowance from U.S. App

Affiliated with

Also associated with

Rating

PDK-1/Akt signaling inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with PDK-1/Akt signaling inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PDK-1/Akt signaling inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4313282